Imaging agents:

Indications for: VISIPAQUE 270

Intra-arterial: Digital subtraction angiography. IV: CT imaging of the head and body, excretory urography, and peripheral venography.

Adult Dosage:

≥12yrs: Usual single doses: Intra-arterial (digital subtraction angiography): Renal arteries: 10–25mL; Aortography: 20–50mL; Major branches of aorta: 5–30mL; max 250mL. IV: CT of head or body: 75–150mL or 100–150mL bolus infusion; max 150mL. Excretory urography (normal renal function): 1mL/kg; max 100mL. Venography (per lower extremity): 50–150mL; max 250mL.

Children Dosage:

<12yrs: IV: CT or excretory urography: 1–2mL/kg; max 2mL/kg.

VISIPAQUE 270 Contraindications:

Intrathecal use.

Boxed Warning:

Not for intrathecal use.

VISIPAQUE 270 Warnings/Precautions:

Have resuscitation equipment and trained personnel available. Homocystinuria: avoid. Severe renal impairment. Cardiovascular disease. CHF. Diabetes. Advanced vascular disease. Multiple myeloma/paraproteinaceous diseases. Pheochromocytoma. Catecholamine-secreting paragangliomas. Thyroid dysfunction (esp. children 0–3yrs); monitor. Homozygous sickle cell disease. History of severe cutaneous adverse reactions: avoid. Maintain adequate hydration. Avoid extravasation. Children: asthma, cyanotic and acyanotic heart disease, CHF, serum creatinine >1.5mg/dL, immature renal function, dehydration: increased risk of adverse effects. Elderly. Pregnancy. Nursing mothers: not recommended.

See Also:

VISIPAQUE 270 Classification:

Radiographic contrast medium.

VISIPAQUE 270 Interactions:

May increase risk of metformin-induced lactic acidosis. Recently received cholecystographic agents in patients with hepatic or biliary disorder; increased risk of renal toxicity. Do not mix with other drugs. Caution with concomitant beta-blockers. Do not use laxatives, diuretics, or preparatory dehydration prior to administration. Radioactive iodine uptake studies may not accurately reflect thyroid function for at least 16 days.

Adverse Reactions:

Rash, erythema, pruritus, scotoma; acute kidney injury, thromboembolic events, hypersensitivity reactions, others.

Drug Elimination:

  • Renal (97%), fecal (<2%).

  • Half-life: 2.1 hours (adults).

Generic Drug Availability:


How Supplied:

Bottles (50mL, 100mL, 150mL, 200mL)—10